References
- Lahtinen R., Laakso M., Palva L., Virkkunen P., Elomaa I. “Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma”. The Lancet 1992; 340: 1049–1052
- Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M., Blacklock H., Bell R., Simeone J. F., Reitsma D. J., Heffernan M., Seman J., Knight R. D. “Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events”. Journal of Clinical Oncology 1998; 16: 593–602
- Musto P. “The role of bisphosphonates for the treatment of bone disease in multiple myeloma”. Leukemia and Lymphoma 1998; 31: 453–462
- Mc Closkey E. V., Dunn J. A., Kanis J. A., Mc Lennan I. C., Drayson M. T. “Long-term follow up of a prospective, double-blind, placebo-controlled trial of clodronate in multiple myeloma”. British Journal of Haematology 2001; 113: 1035–1043
- Berenson J. R., Rosen L. S., Howell A., Porter L., Coleman R. E., Morley W., Dreicer R., Kurosa R. A., Lipton A., Seaman J. J. “Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double blind, randomised dose-response study”. Cancer 2001; 91: 1191–1200
- Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., Lichtenstein A. “In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates”. Leukemia 1998; 12: 220–229
- Dhodapkar M. V., Singh J., Mehta J., Fassas A., Desikan K. R., Perlman M., Munshi N. K., Barlogie B. “Anti-myeloma activity of pamidronate in vivo“. British Journal of Haematology 1998; 103: 530–532
- Corso A., Astori C., Orlandi E., Zappasodi P., Arcaini L., Bernasconi P. “Transient response of myeloma clone to pamidronate therapy”. Haematologica 1999; 84: 759–760
- Kunzmann V., Bauer E., Feurle J., Weissinger F., Tony H. P., Wilhelm M. “Stimulations of T-cells by aminobis-phosphonates and induction of anti-plasma cell activity in multiple myeloma”. Blood 2002; 96: 384–393
- Musto P., Falcone A., Sanpaolo G., La Sala A., Mantuano S., Cascavilla N., Melillo L., Dell'Olio M., Nobile M., Bodenizza C., Carella A. M. “A combined therapy with thalidomide. dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma”. Blood 2002; 100: 388b, Abstract
- Durie B. G.M., Salmon S. E. “Clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival”. Cancer 1975; 36: 842–848
- Thurlimann B., Morant R., Jungi W. F., Radziwill A. “Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective, dose-effect study”. Supportive Care Cancer 1994; 2: 61–65
- Berenson J. R., Hillner B. E., Kyle R. A., Anderson K., Lipton A., Yee G. C., Biermann S. “American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma”. Journal of Clinical Oncology 2002; 20: 3719–3736
- Martin A., Garcia-Sanz R., Hernandez J., Blede' J., Suquia B., Fernandez-Calvo J., Gonzalez M., Mateo G., Orfao A., San J. F. Miguel. “Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumor effect”. British Journal of Haematology 2002; 118: 239–242
- Rosen L. S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J. A., Apffelstaedt J., Tfrin M., Hussein M., Coleman R. E., Reitsma D. J., Seaman J. J., Chen B. L., Ambros I. “Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial”. Cancer Journal 2001; 7: 377–387